Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency

Bone

Volumn 141, Issue , 2020, Pages

  Frazier, Rebecca ^a,b   Hodakowski, Alexander ^a   Cai, Xuan ^a   Lee, Jungwha ^a   Zakarija, Anaadriana ^a   Stein, Brady ^a   David, Valentin ^a   Wolf, Myles ^c   Isakova, Tamara ^a   Mehta, Rupal ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Bone specific alkaline phosphatase; Ferric carboxymaltose; Fibroblast growth factor 23; Hypophosphatemia; Iron deficiency anemia

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITRIOL; CALCIUM; FERRIC CARBOXYMALTOSE; FERRITIN; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN; IRON; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; SODIUM DIHYDROGEN PHOSPHATE; TRANSFERRIN; FERRIC ION; MALTOSE; MINERAL;

ADULT; ARTICLE; BONE MINERALIZATION; CLINICAL ARTICLE; DRUG SAFETY; FEMALE; HUMAN; HYPOPHOSPHATEMIA; IRON DEFICIENCY ANEMIA; OBSERVATIONAL STUDY; PHOSPHATE EXCRETION; PROSPECTIVE STUDY;

ANEMIA, IRON-DEFICIENCY; FEMALE; FERRIC COMPOUNDS; HUMANS; MALTOSE; MINERALS;

EID: 85090016854     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2020.115559     Document Type: Article

References (28)

1. Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet (London, England). 2007;370(9586):511–520.
2. McLean, E., Cogswell, M., Egli, I., Wojdyla, D., de Benoist, B., Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutr. 12:4 (2009), 444–454.
3. Auerbach, M., Macdougall, I., The available intravenous iron formulations: history, efficacy, and toxicology. Hemodial. Int. 21:Suppl. 1 (2017), S83–s92.
4. Van Wyck, D.B., Mangione, A., Morrison, J., Hadley, P.E., Jehle, J.A., Goodnough, L.T., Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 49:12 (2009), 2719–2728.
5. Keating, G.M., Ferric carboxymaltose: a review of its use in iron deficiency. Drugs. 75:1 (2015), 101–127.
6. Wolf, M., White, K.E., Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr. Opin. Nephrol. Hypertens. 23:4 (2014), 411–419.
7. Wolf, M., Koch, T.A., Bregman, D.B., Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J. Bone Miner. Res. 28:8 (2013), 1793–1803.
8. Yamazaki, Y., Okazaki, R., Shibata, M., et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin. Endocrinol. Metab. 87:11 (2002), 4957–4960.
9. Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018;3(23).
10. Schaefer, B., Glodny, B., Zoller, H., Blood and bone loser. Gastroenterology. 152:6 (2017), e5–e6.
11. Bartko, J., Roschger, P., Zandieh, S., Brehm, A., Zwerina, J., Klaushofer, K., Hypophosphatemia, severe bone pain, gait disturbance, and fatigue fractures after iron substitution in inflammatory bowel disease: a case report. J. Bone Miner. Res. 33:3 (2018), 534–539.
12. Klein, K., Asaad, S., Econs, M., Rubin, J.E., Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ case reports., 2018, 2018.
13. Moore KL, Kildahl-Andersen O, Kildahl-Andersen R, Tjonnfjord GE. Uncommon adverse effect of a common medication. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke. 2013;133(2):165.
14. Urbina, T., Belkhir, R., Rossi, G., et al. Iron supplementation-induced phosphaturic osteomalacia: FGF23 is the culprit. J. Bone Miner. Res. 33:3 (2018), 540–542.
15. Maffioli P, Derosa G. Overview of Biochemical Markers of Bone Metabolism. In: Patel VB, Preedy VR, eds. Biomarkers in Bone Disease. Netherlands: Springer, Dordrecht; 2017:3–21.
16. Bermejo, F., García-López, S., A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J. Gastroenterol. 15:37 (2009), 4638–4643.
17. World Health Organization, Centers for Disease Control and Prevention. Assessing the Iron Status of Populations: Second edition, Including Literature Reviews. 2007.
18. Food and Drug Administration. Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical. 2007.
19. Laha, T.J., Strathmann, F.G., Wang, Z., de Boer, I.H., Thummel, K.E., Hoofnagle, A.N., Characterizing antibody cross-reactivity for immunoaffinity purification of analytes prior to multiplexed liquid chromatography-tandem mass spectrometry. Clin. Chem. 58:12 (2012), 1711–1716.
20. Detlie, T.E., Lindstrom, J.C., Jahnsen, M.E., et al. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. Aliment. Pharmacol. Ther. 50:4 (2019), 397–406.
21. Blazevic, A., Hunze, J., Boots, J.M., Severe hypophosphataemia after intravenous iron administration. Neth. J. Med. 72:1 (2014), 49–53.
22. Fierz, Y.C., Kenmeni, R., Gonthier, A., Lier, F., Pralong, F., Coti, Bertrand P., Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient. Eur. J. Clin. Nutr. 68:4 (2014), 531–533.
23. Mani, L.Y., Nseir, G., Venetz, J.P., Pascual, M., Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient. Transplantation. 90:7 (2010), 804–805.
24. Takashi, Y., Fukumoto, S., FGF23 beyond phosphotropic hormone. Trends Endocrinol Metab 29:11 (2018), 755–767.
25. White KE, Econs MJ. Fibroblast growth factor-23. In: Rosen CJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 7 ed. 2025 M Street, NW, Suite 800, Washington, DC 20036: Americal Society for Bone and Mineral Research; 2008:112–116.
26. Amarnani R, Travis S, Javaid MK. Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia. Rheumatology (Oxford, England). 2020.
27. Song, L., Calcium and bone metabolism indices. Adv. Clin. Chem. 82 (2017), 1–46.
28. Ross, P.D., Knowlton, W., Rapid bone loss is associated with increased levels of biochemical markers. J. Bone Miner. Res. 13:2 (1998), 297–302.